Investors Sell Pfizer Inc. (PFE) on Strength (PFE)
Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Tuesday. $58.18 million flowed into the stock on the tick-up and $119.13 million flowed out of the stock on the tick-down, for a money net flow of $60.95 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.29 for the day and closed at $35.11
PFE has been the subject of a number of research analyst reports. Jefferies Group set a $41.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, May 11th. Bank of America Corp. reiterated a “buy” rating and set a $28.25 price objective (down previously from $38.48) on shares of Pfizer in a report on Tuesday, May 10th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a report on Friday, May 6th. BMO Capital Markets restated a “buy” rating and issued a $40.00 price target (up previously from $39.00) on shares of Pfizer in a report on Wednesday, May 4th. Finally, Sanford C. Bernstein set a $36.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, May 3rd. Ten analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.82.
The stock’s 50-day moving average is $35.78 and its 200-day moving average is $33.42. The stock has a market capitalization of $211.57 billion and a PE ratio of 30.92.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.56 EPS. On average, equities analysts anticipate that Pfizer Inc. will post $2.46 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Friday, August 5th will be issued a dividend of $0.30 per share. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 dividend on an annualized basis and a yield of 3.44%.
A number of hedge funds recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in Pfizer by 16.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,378,870 shares of the biopharmaceutical company’s stock worth $786,951,000 after buying an additional 3,522,873 shares during the last quarter. Boys Arnold & Co. Inc. raised its position in shares of Pfizer by 72.7% in the fourth quarter. Boys Arnold & Co. Inc. now owns 258,541 shares of the biopharmaceutical company’s stock worth $8,346,000 after buying an additional 108,831 shares during the period. Novare Capital Management LLC raised its position in shares of Pfizer by 0.8% in the fourth quarter. Novare Capital Management LLC now owns 204,262 shares of the biopharmaceutical company’s stock worth $6,594,000 after buying an additional 1,590 shares during the period. SNS Financial Group LLC raised its position in shares of Pfizer by 9.1% in the fourth quarter. SNS Financial Group LLC now owns 62,206 shares of the biopharmaceutical company’s stock worth $2,008,000 after buying an additional 5,192 shares during the period. Finally, CAM Group Holding A S raised its position in shares of Pfizer by 111.2% in the fourth quarter. CAM Group Holding A S now owns 1,148,915 shares of the biopharmaceutical company’s stock worth $37,087,000 after buying an additional 605,000 shares during the period.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.